EyeGene,Inc Application to Amend Korean Phase 2/3 Trial Plan for Quadrivalent Meningococcal Conjugate Vaccine EG-MCV4
AI summary · Not investment advice
The company applied to the MFDS on 2026-11-10 to amend the Korean Phase 2/3 trial plan for its quadrivalent meningococcal vaccine EG-MCV4.
Commentary
AI commentary · Not investment advice
What happened
Aegis-type filing: the company applied to Korea's Ministry of Food and Drug Safety (MFDS) to change the plan for its Phase 2/3 trial of EG-MCV4, a 4-strain meningococcal vaccine. The trial tests immune response and safety in healthy adults. It runs at multiple hospitals, including Eunpyeong St. Mary's Hospital of the Catholic University of Korea.
In the company's terms
The change reflects supplementary requests from the MFDS. Part 1 is Phase 2 with a target of 125 participants. Part 2 is Phase 3 with a target of 998 participants, split into Cohort A with 730 and Cohort B with 268.
What changes for shareholders
The trial period is 30 months from the approval date of the institutional review board (IRB). It can be extended depending on how long participant recruitment takes. The materials do not say when the change will be approved.
Earlier filings of the same type
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.11.122026.11.12 | Nov 12, 2026 · Date MFDS approved the clinical trial plan amendment application |
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
E